REVO Oncology
Precision Cancer Treatment, AI
Predict who will respond to chemotherapy before the patient is treated for all cancer.
How We Help
Leadership
Problem Statement
Millions of cancer patients suffer from non-optimized treatments, leading to suboptimal outcomes and unnecessary side effects. Current approaches fail to personalize care for many, particularly the 85% of patients in early-stage cancer and minimal residual disease, leading to a significant unmet need for precision medicine and better chemoresponse prediction.
Core Technology
An AI-powered genomics platform designed to personalize cancer treatment.
Key Differentiators
A single AI platform capable of scaling across multiple oncology applications, a leadership team with a track record of globally launching over 20 diagnostics and changing the standard of care 23 times, and an exclusive IP agreement providing a defensible moat.
Clinical Focus
Oncology (Chemoresponse, ADC & PARP inhibitor selection, Early-stage cancer, Minimal Residual Disease)
Target Customers
Biopharma, diagnostic test providers, technology providers, and hospitals.
Product Stage
GA (for initial use cases), with active development for others
Company Info
- Business Model
- B2B (Platform-as-a-Service for biopharma, diagnostic test providers, and hospitals)
Categories
Technologies
Clinical & IP
Clinical Validation
Engaged in a signed Phase III clinical trial and planning a Clinical Utility Study following seed funding to optimize and lock in clinical performance.
IP Protection
Signed IP Term Sheet locking up exclusivity; an exclusive IP Agreement is pending signature.
Only accessible to MedStartr community members.
Join nowWhat do you think of REVO Oncology?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.